C07K 2319/75
Containing a fusion for activation of a cell surface receptor
Official title: containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones
C07K2319/75 (Containing a fusion for activation of a cell surface receptor) appears on 795 US grants and 555 published applications in this corpus.
Search patents in C07K- Granted patents
- 795
- Published applications
- 555
- Assignees
- 434
- Inventors
- 1,662
- Latest grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 2 | 0 |
| 1983 | 1 | 0 |
| 1984 | 0 | 0 |
| 1985 | 2 | 0 |
| 1986 | 5 | 0 |
| 1987 | 11 | 0 |
| 1988 | 15 | 0 |
| 1989 | 17 | 0 |
| 1990 | 11 | 0 |
| 1991 | 23 | 0 |
| 1992 | 27 | 0 |
| 1993 | 31 | 0 |
| 1994 | 29 | 0 |
| 1995 | 26 | 0 |
| 1996 | 31 | 0 |
| 1997 | 52 | 0 |
| 1998 | 49 | 0 |
| 1999 | 40 | 0 |
| 2000 | 34 | 0 |
| 2001 | 29 | 3 |
| 2002 | 29 | 32 |
| 2003 | 23 | 39 |
| 2004 | 12 | 28 |
| 2005 | 15 | 25 |
| 2006 | 19 | 22 |
| 2007 | 16 | 13 |
| 2008 | 12 | 17 |
| 2009 | 16 | 20 |
| 2010 | 13 | 16 |
| 2011 | 15 | 13 |
| 2012 | 9 | 16 |
| 2013 | 14 | 10 |
| 2014 | 8 | 11 |
| 2015 | 14 | 14 |
| 2016 | 11 | 17 |
| 2017 | 12 | 23 |
| 2018 | 11 | 28 |
| 2019 | 17 | 23 |
| 2020 | 14 | 26 |
| 2021 | 10 | 18 |
| 2022 | 23 | 44 |
| 2023 | 12 | 27 |
| 2024 | 12 | 23 |
| 2025 | 17 | 31 |
| 2026 | 6 | 16 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Selective stimulation of T cells in solid tumors using oncolytic viral delivery of orthogonal IL-223 Jun 2026US 12,661,401 B2The Regents of the University of California
- Bispecific antibodies specifically binding to PD1 and LAG328 Apr 2026US 12,611,457 B2Hoffmnn-La Roche Inc.
- Anti-PD-1 antibodies and fusion proteins28 Apr 2026US 12,612,460 B2Kadmon Corporation, LLC
- Engineered immune cells with micro-clusters7 Apr 2026US 12,595,291 B2A2 Biotherapeutics, Inc.
- Recombinant proteins with CD40 activating properties17 Mar 2026US 12,576,147 B2Assistance Publique-HôPitaux De Paris (Aphp)
- Engineered immune cells with receptor cross-talk6 Aug 2026US 2026/0226135 A1A2 Biotherapeutics, Inc.
- Compositions and Methods for Targeted Delivery of TGFß30 Jul 2026US 2026/0217778 A1Regeneron Pharmaceuticals, Inc.
- Anti-PD-1 Antibodies and Fusion Proteins30 Jul 2026US 2026/0217831 A1Kadmon Corporation, LLC
- Interleukin-2/interleukin-2 receptor alpha fusion proteins and methods of use23 Jul 2026US 2026/0207709 A1Bristol-Myers Squibb Company
- Engineered immune cells with receptor signal strength modulated by a hinge16 Jul 2026US 2026/0201012 A1A2 Biotherapeutics, Inc.
Most cited
By later US patents
- Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants660US 5,750,373 AGenentech, Inc. · 1998
- Monovalent phage display562US 5,821,047 AGenentech, Inc. · 1998
- Production of vascular endothelial cell growth factor406US 5,194,596 ACalifornia Biotechnology Inc. · 1993
- Expression using fused genes providing for protein product297US 4,751,180 AChiron Corporation · 1988
- Expression and export technology of proteins as immunofusins276US 5,541,087 AFuji ImmunoPharmaceuticals Corporation · 1996